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Objectives: this study investigates current practice of risk factor documentation in a vascular unit and compares
variations in risk factor assessment between elective and emergency admissions.
Methods: one hundred and forty-four patients who underwent vascular surgical intervention for atherosclerotic disease
during the year 2000 were retrospectively identified from computerised database. Case note review collated demographic
details, data on risk factor assessment and the nature of surgery. Data were analysed using SPSS statistical software.
Results: the male to female ratio was 2.3:1 with a median (range) age of 73 (31±95) years. For 55 (38%) emergency
admissions the following risk factors were not documented; ischaemic heart disease (8), diabetes mellitus (10), hypertension
(10), smoking habit (13) and antiplatelet therapy (18). For 89 (62%) elective admissions the following risk factors were not
documented; ischaemic heart disease (11), diabetes mellitus (9), hypertension (4), smoking habit (5) and antiplatelet therapy
(19). Sixty-six (72.5%) routine admissions and 11 (20.8%) emergency admissions had estimations of serum cholesterol
documented ({\chi}2 p5 0.001). There were no statistically significant differences in the documentation of other risk
factors between the 2 groups.
Conclusion: risk factors are not documented consistently for emergency vascular surgical admissions. Staff education
should aim to improve risk factor assessment for elective and emergency admissions to reduce cardiovascular events and
possibly improve surgical outcome in patients with atherosclerotic disease.
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Background
Seventy per cent of patients with peripheral arterial
occlusive disease (PAOD) have ischaemic heart disease
(IHD) and their 10 year mortality, largely due to cardiac
events or stroke, is approximately 50% greater than
patients without peripheral vascular disease.1 IHD is
also prevalent in patients with abdominal aortic aneur-
ysm (AAA) and accounts for most of the morbidity and
mortality in these patients in the short term after surgi-
cal repair and on long-term follow up.2
Atheroma can undergo episodes of increased bio-
logical activity with subsequent intra-plaque haemor-
rhage or rupture. These sudden changes may either
occlude a vessel or expose the subintimal surface
promoting thrombosis. Most acute ischaemic events
in the coronary circulation are associated with the
process of atherothrombosis.3 The same may be true
of events in the cerebral circulation.
A focused approach to the management of patients
admitted under the care of vascular surgeons should
include measures to reduce the progression of arterio-
sclerosis by modifying risk factors where possible. The
potential benefits include improving cardiovascular
morbidity and mortality, reducing progression of
local disease and optimizing the long-term benefit of
revascularisation procedures. Lack of direct evidence
of benefit and concerns about cost effectiveness may
have limited the widespread application of an aggres-
sive approach to treatment of risk factors.4
The aim of the current study was to observe the
practice of risk factor documentation in emergency
and elective admissions to a specialist vascular
surgical unit.
Patients and Methods
One hundred and forty-four patients who underwent
vascular surgical procedures during the year 2000
were identified from a computerised database. Case
note review collated demographic details and details
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of surgical procedures performed. The documentation
of risk factors including smoking habit, diabetes
mellitus, IHD, hypertension, hypercholesterolaemia
and antiplatelet medication was noted. Positive docu-
mentation of antiplatelet medication was accepted if
a contraindication to prescription of antiplatelet ther-
apy was written in the patients notes or if a patient
was on warfarin on admission. Positive documenta-
tion of hypercholesterolaemia was accepted if patients
reported elevated cholesterol levels on admission, if
cholesterol lowering drugs were noted or if serum
cholesterol level was checked during admission or
follow up.
Admission notes, discharge summaries and clinic
letters were reviewed for evidence of documentation
of the risk factors listed above. If patients underwent
more than one operation during a single admission
they were classified according to initial operation and
were only included once for analysis. All patients
were reviewed by a consultant vascular surgeon dur-
ing admission.
Differences in the documentation of risk factors
between elective and emergency admissions were
compared on SPSS software using the Chi-squared
test for discontinuous data.
Results
There were 101 males and 43 females (m:f 2.3:1). The
median age at admission was 73 (range 31±95) years.
Fifty-five (38%) patients were admitted as emergencies.
Operations performed included AAA repair (40),
carotid endarterectomy (31), infrainguinal bypass
(28), major amputation (27), aortobifemoral bypass
(5) and 13 other arterial procedures.
In total seventy-seven (54%) patients had estimation
of serum cholesterol either in a preoperative clinic,
during in-patient stay or on out-patient follow up.
Sixty-six (73%) elective admissions had serum choles-
terol documented compared to 11 (21%) emergency
admissions (p5 0.001). The documentation of other
risk factors displayed a similar pattern with emer-
gency admissions having less complete documenta-
tion but the differences between elective and
emergency admissions failed to reach statistical sig-
nificance. These results are shown in Figure 1.
A positive or negative history of IHD was documen-
ted in 125 (87%) patients. Of the 89 elective admissions
78 (88%) had history of IHD documented and of the 55
emergency admissions 47 (85%) had a history of IHD
documented (pn.s.).
A previous diagnosis of diabetes mellitus was
recorded in 80 (90%) elective patients and 45 (81.8%)
emergency patients (pn.s.). A positive or negative
history of hypertension was documented in 85 (96%)
of the elective cases and 45 (82%) of the emergencies
(pn.s.). Smoking status as either a current, ex, or
non-smoker was recorded for 84 (94%) elective admis-
sions but only 42 (76%) emergency admissions (pn.s.).
Antiplatelet therapy or contraindication for antipla-
telet therapy was recorded in 70 (79%) elective but
only 37 (67%) emergency admissions (pn.s.).
Discussion
When considering the role of risk factor manipulation
the potential benefit to a patient must be weighed
against the cost of identifying and then treating the
risk factor. Patients may need follow up appointments
with vascular surgeons or other clinicians to monitor
the efficacy of any risk modifying treatment and may
need serial investigations. Most of the interventions
considered in this paper are safe with a low incidence
of serious side effects but some, such as statin therapy
for hypercholesterolaemia, are relatively expensive.
Risk factors such as hyperhomocysteinaemia and
hormone replacement therapy (HRT) in post meno-
pausal women were not examined in the current
audit. Hyperhomocysteinaemia is a relatively recently
recognised independent risk factor for PAOD and was
not routinely measured in our unit at the time of this
study. In addition the impact on cardiovascular end-
points of treating hyperhomocysteinaemia needs fur-
ther evaluation. The prescription of HRT is probably
addressed best by doctors with a special interest in
womens health.
Fig. 1. Number of patients with risk factors not documented. 2
p 0.001.
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Cigarette smoking
Cigarette smoking is one of the most important risk
factors for atherosclerosis5 and is associated with a
3-fold increased risk for PAOD.6 Current smokers are
at higher risk than former smokers and a greater
number of pack years is associated with more severe
disease.7 Smoking also affects PAOD outcomes in that
progression from intermittent claudication to rest pain
occurs more frequently in smokers8±10 and amputation
rates are 2±3 times higher in smokers.11 Survival is
also significantly worse in individuals who continue
to smoke.8
In the current study 94% of elective and 76% of
emergency admissions had their smoking status
recorded. This is a disappointingly low documentation
rate for emergency admissions. There are no clinics in
our hospital Trust dedicated to smoking cessation.
This may be a reflection of the low long-term cessation
rates for antismoking interventions.8,12±14
While general practitioners are probably the best
clinicians to oversee efforts to encourage patients to
give up smoking, patient education from vascular
surgical teams may also be of benefit in this endeavor.
Assessment of smoking habits should be an
integral part of history taking from vascular surgical
patients.
Diabetes mellitus
The Framingham Trial showed that the age adjusted
risk ratio for developing intermittent claudication in
diabetics was increased by a factor of 5 in men and a
factor of 3 in women at 16 year follow up.15,16
The population of patients studied had the presence
or absence of diabetes mellitus recorded in 90% of
non-emergency but only 82% of emergency admis-
sions. Ten per cent of routine admissions and eighteen
percent of emergency admissions may therefore have
had an opportunity for improved management of
their diabetes missed. Documentation of a risk factor
does not necessarily equate to appropriate manage-
ment of that risk factor and the current audit did not
attempt to analyse optimal or appropriate modifica-
tion of risk factors. This should be the subject of future
prospective audit.
Stringent control of blood glucose has been demon-
strated to be of benefit in prevention of microvascular
complications but less is known about its role in
macrovascular disease. The United Kingdom Pro-
spective Diabetes Study Group documented that the
risk of amputation was not altered by intensive gly-
caemic control.17
Hyperlipidaemia
Dyslipidaemias are a major risk factor for all forms
of atherosclerosis. Large epidemiological trials have
shown that abnormal lipid metabolism is independ-
ently associated with cardiovascular mortality.18±20
The platelets of hyperlipidaemic patients are abnor-
mally sensitive to activation21 and treatment of dysli-
pidaemias ameliorates this tendency to thrombosis.22
In addition the risk of acute cardiovascular events is
increased by changes in blood viscosity and coagula-
tion factors23 while treatment of underlying lipid
abnormalities can normalise these markers.24 There
is also impaired endothelial function in this group of
patients which can contribute to vasospasm. The
effects of lipid lowering on endothelial function
appear beneficial.25
Meta-analyses have been used to evaluate results
of all the cholesterol lowering trials26,27 and conclude
that patients with cardiovascular disease should
reduce LDL cholesterol levels to  100 mg/dl. In
patients with peripheral atherosclerosis cholesterol
lowering treatment has been associated with stabiliza-
tion or regression of atheromatous plaques28 and a
reduction in the risk of new or worsening intermittent
claudication.29
Despite the evidence that statin therapy is beneficial
in patients with atherosclerosis one quarter of elective
vascular admissions reviewed in this audit had no
documentation that hypercholesterolaemia was inves-
tigated or considered during their admission. The
management of mild dyslipidaemias in an elderly
population might be considered a contentious issue
when the cost of treatment is considered and may
explain the results presented. Although urgent treat-
ment of hypercholesterolaemia may not effect out-
come for acute admissions overlooked investigation
at this stage is a missed opportunity to improve long-
term prognosis.
Hypertension
High blood pressure is a well-recognised risk factor
for atherosclerotic disease, particularly cerebrovascu-
lar and IHD.30 In PAOD hypertension increases risk
approximately 2±3 fold.6,31
Meta-analysis suggests that appropriate treatment
of hypertension reduces all cause mortality by 12%,
stroke mortality by 36% and coronary heart disease
mortality by 25%.32
In the current study 18% of emergency admissions
and 10% of elective admissions did not have the pres-
ence or absence of hypertension recorded. Intensive
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control of blood pressure in liaison with general prac-
titioners and cardiologists may improve prognosis for
vascular surgical admissions. Admission to hospital
should be regarded as a valuable opportunity to
screen, identify and when indicated modify this
important risk factor.
Antiplatelet therapy
The role of platelets in thrombus formation has led
to the use of antiplatelet agents, particularly aspirin,
in the prevention of acute ischaemic events.
Seventy-nine per cent of elective admissions and
67% of emergency admissions had documentation in
their notes that antiplatelet therapy had been consid-
ered. Although resistance to antiplatelet agents is an
increasingly recognised problem in patients with car-
diovascular disease all patients should be prescribed
an inhibitor of platelet adhesion or activation unless
contraindicated.
The Clopidogrel vs Aspirin for the prevention of
ischaemic events (CAPRIE) trial compared the bene-
fits of two antiplatelet agents in the prevention of fatal
or non fatal stroke or myocardial infarction or other
vascular death.33 Over 6000 patients were recruited in
the CAPRIE trial on the basis of having PAOD. This
subgroup of patients had a 23.8% risk reduction on
clopidogrel.
Summary
In this study documentation of the established inde-
pendent risk factors for vascular disease was exam-
ined. There is no evidence to suggest that emergency
admissions are less likely to benefit from risk factor
assessment than elective patients in terms of cardio-
vascular health and improved prognosis for vascular
intervention. Our results suggest that recording of all
risk factors was less complete in emergency compared
to elective admissions although only differences in
documentation of serum cholesterol reached statistical
significance. This difference between elective and
emergency admissions may, in part, be explained by
time pressure surrounding some vascular emergen-
cies at admission but also highlights a missed oppor-
tunity to address risk factors during subsequent out
patient follow up of urgent cases. Out of hours admis-
sion by `` on call'' teams with limited exposure to work
on a vascular surgical unit may also explain discre-
pancies in the documentation of risk factors.
In the United Kingdom, most patients with vascular
disease will be managed by vascular surgeons and
general practitioners. The responsibility to manage
risk factors must lie with these two clinicians but
input from nursing staff, diabetologists, chemical
pathologists and cardiologists along with the
implementation of care pathways and protocols for
the treatment of risk factors might improve care.
With a multidisciplinary approach, tackling the modi-
fiable risk factors of cardiovascular disease could have
a significant impact on patient survival and quality of
life for vascular surgical admissions.
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